Carnegie Investment Counsel Has $77.97 Million Stock Position in Stryker Corporation $SYK

Carnegie Investment Counsel grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 9.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 242,981 shares of the medical technology company’s stock after acquiring an additional 21,122 shares during the period. Stryker makes up approximately 1.5% of Carnegie Investment Counsel’s portfolio, making the stock its 10th largest holding. Carnegie Investment Counsel’s holdings in Stryker were worth $77,973,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. VanderPol Investments L.L.C. grew its stake in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after acquiring an additional 28 shares during the last quarter. KCM Investment Advisors LLC raised its position in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC boosted its stake in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC grew its position in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp increased its stake in Stryker by 1.2% during the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. UBS Group decreased their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Truist Financial reissued a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Leerink Partners decreased their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Canaccord Genuity Group lowered their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $392.87.

Stryker Stock Performance

Shares of SYK stock traded up $2.75 during trading hours on Friday, reaching $329.86. The company had a trading volume of 2,724,614 shares, compared to its average volume of 2,471,298. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The business has a fifty day moving average price of $310.12 and a 200-day moving average price of $337.97. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The firm has a market cap of $126.46 billion, a PE ratio of 38.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter last year, the company earned $2.84 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.